BOTOX® Prophylaxis in Patients With Chronic Migraine
Completed
- Conditions
- Migraine Disorders
- Interventions
- Biological: botulinum toxin Type A
- First Posted Date
- 2011-09-13
- Last Posted Date
- 2019-01-08
- Lead Sponsor
- Allergan
- Target Recruit Count
- 1168
- Registration Number
- NCT01432379
Safety and Efficacy Study of Ozurdex® Compared to Lucentis® in Patients With Branch Retinal Vein Occlusion
Phase 4
Completed
- Conditions
- Retinal Vein OcclusionMacular Edema
- Interventions
- Biological: ranibizumab
- First Posted Date
- 2011-09-02
- Last Posted Date
- 2019-04-18
- Lead Sponsor
- Allergan
- Target Recruit Count
- 307
- Registration Number
- NCT01427751
A Study of the Safety and Efficacy of Bimatoprost Ophthalmic Solution in Paediatric Patients With Glaucoma
Phase 3
Terminated
- Conditions
- Glaucoma
- Interventions
- First Posted Date
- 2011-08-31
- Last Posted Date
- 2015-10-02
- Lead Sponsor
- Allergan
- Target Recruit Count
- 6
- Registration Number
- NCT01426113
Pharmacokinetics Study of Dapsone-Adapalene Fixed Combination Gel in Acne
Phase 1
Withdrawn
- Conditions
- Acne Vulgaris
- Interventions
- Drug: Fixed Combination dapsone/adapalene Formulation A GelDrug: Fixed Combination dapsone/adapalene Formulation B Gel
- First Posted Date
- 2011-08-30
- Last Posted Date
- 2012-11-19
- Lead Sponsor
- Allergan
- Registration Number
- NCT01425320
Inter-rater and Intra-rater Reliability of the Global Eyebrow Assessment Scale
- First Posted Date
- 2011-08-09
- Last Posted Date
- 2012-10-29
- Lead Sponsor
- Allergan
- Target Recruit Count
- 112
- Registration Number
- NCT01412086
Retrospective Study in Patients Receiving Two or More OZURDEX® Injections for Retinal Vein Occlusion (RVO)
Completed
- Conditions
- Retinal Vein OcclusionMacular Edema
- Interventions
- First Posted Date
- 2011-08-08
- Last Posted Date
- 2013-04-16
- Lead Sponsor
- Allergan
- Target Recruit Count
- 289
- Registration Number
- NCT01411696
Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)
Phase 2
Completed
- Conditions
- Age-related Macular Degeneration
- Interventions
- First Posted Date
- 2011-07-19
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Allergan
- Target Recruit Count
- 271
- Registration Number
- NCT01397409
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Forehead and Frown Lines
Not Applicable
Completed
- Conditions
- Facial RhytidesGlabellar Frown Lines
- Interventions
- Biological: botulinum toxin Type ADrug: Normal Saline
- First Posted Date
- 2011-07-12
- Last Posted Date
- 2019-04-17
- Lead Sponsor
- Allergan
- Target Recruit Count
- 175
- Registration Number
- NCT01391299
Safety and Efficacy Study of Bimatoprost in Japanese Patients With Eyelash Hypotrichosis
Phase 3
Completed
- Conditions
- Eyelash Hypotrichosis
- Interventions
- First Posted Date
- 2011-07-12
- Last Posted Date
- 2019-07-08
- Lead Sponsor
- Allergan
- Target Recruit Count
- 173
- Registration Number
- NCT01391273
Patient Satisfaction Study of BOTOX® Cosmetic in the Treatment of Moderate to Severe Frown Lines
Phase 4
Completed
- Conditions
- Glabellar Frown Lines
- Interventions
- Drug: normal saline (placebo)Biological: botulinum toxin Type A
- First Posted Date
- 2011-07-12
- Last Posted Date
- 2012-09-25
- Lead Sponsor
- Allergan
- Target Recruit Count
- 40
- Registration Number
- NCT01391312
© Copyright 2025. All Rights Reserved by MedPath